People Dr Paul Fairchild
University Lecturer in the Immunobiology of Stem Cells and Oxford Martin Senior Fellow, Oxford Martin School
University Lecturer in the Immunobiology of Stem Cells
Paul Fairchild was Co-Director of the Oxford Stem Cell Institute from 2008-2015, which was funded by the Oxford Martin School during this period. He remains connected with the School through his role as an Oxford Martin Senior Fellow.
Paul's research addresses the immunological barriers to stem cell therapies.
After obtaining a first class degree and an award for top graduate in the Biological Sciences, Paul Fairchild began his research career in Oxford, where he studied for a DPhil within the Nuffield Department of Surgery, focussing on the immune response to organ allografts. After spending five years as a Post Doctoral Fellow in the Department of Pathology, University of Cambridge, he returned to Oxford where he is currently a lecturer and RCUK Academic Fellow within the Sir William Dunn School of Pathology. Here he has applied his immunological training to the emerging field of cell replacement therapy and regenerative medicine to investigate the immune response to tissues differentiated from embryonic stem cells, the rejection of which threatens to undermine the success of regenerative medicine in the future. He has developed strategies which may one day promote the indefinite survival of stem cell-derived grafts and is currently collaborating with Geron Corporation to bring such technology to the clinic.
Oxford Martin School
University Lecturer in the Immunobiology of Stem Cells and Oxford Martin Senior Fellow
- Nov 2011
- Cross-presentation of tumour antigens
- Apr 2011
- Regenerative medicine spoilt for choice
- Dec 2007
- Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance
- Oct 2007
- Embryonic stem cells: protecting pluripotency from alloreactivity
- Jul 2007
- Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation
- Sep 2004
- Embryonic stem cells and the challenge of transplantation tolerance